2023-07-11 12:13:05
Many therapeutic advances once morest female cancers were presented at the annual meeting of the American society of clinical oncology (Asco), at the beginning of June, in Chicago (United States). Among them, the conclusions of the CHIPOR study, the results of which were presented by Pr. Jean-Marc Classe, head of the oncological surgery department at the Western Cancer Institute and coordinating investigator of the study.
The trial was conducted between 2011 and 2021 in 33 centers in France, Belgium, Canada and Spain with 415 patients with cancer of the the ovary in recurrence. In this randomized trial, one arm received treatment with hyperthermic intraperitoneal chemotherapy (CHIP), the other did not. “The Chip is a technique that has existed since the 90s. The intervention consists of a laparotomy. All diseased tissue is removed. After that, we do not close. We leave open another hour during which we place heated chemotherapy directly in the peritoneal cavity, the peritoneum being this layer which lines the internal walls of the abdomen”, explains Prof. Classe.
The Chip is used once morest certain peritoneal diseases and is already part of the therapeutic options in the treatment of ovarian cancer. This is often diagnosed at an advanced stage, with damage to the peritoneum. “The Chip makes it possible to better treat the peritoneum, whereas conventional intravenous chemotherapy achieves this poorly,” specifies the specialist.
Regarding the recurrence of ovarian cancer, in 75 to 80% of cases, it is mainly located on the peritoneum. While the ovaries were removed during a first intervention, the therapeutic options available are then limited. “In 2009, it was hypothesized that the Chip might work in the treatment of these relapsed patients. In 2011, we started our trial,” recalls the scientist. “We were able to show that the chances of survival were higher in the arm treated with Chip than in the one without Chip. Patients treated without Chip have a median survival of 45 months, those treated with Chip saw their survival extended by almost ten months. »
From now on, the objective is to integrate the Chip among the therapeutic options available to caregivers once morest the recurrence of ovarian cancer in the coming months. “Our results still need to be refined but they are extremely encouraging, with a real improvement in the chances of survival in patients with recurrent ovarian cancer. They might transform the way we treat them. In addition, treatment with Chip would not alter their quality of life,” concludes Prof. Classe.
Note: in 2020, the number of newly diagnosed cases of ovarian cancer is estimated at 5,320, making it the 9th leading cause of cancer in women. That same year, 3,935 deaths were recorded, the fifth leading cause of death from cancer. In question, an often late diagnosis which makes the diagnosis more unfavorable.
1689078306
#Recurrence #ovarian #cancer #promising #treatment #patients
